Slide 1: Investor Presentation August 2021
Dimerix Investor Presentation August 2021 @ Dimerix
Slide 2: Forward looking statements
Forward looking statements This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Dimerix to be materially different fro
Slide 3: About Dimerix
About Dimerix Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on inflammatory disease treatments such as kidney and respiratory diseases Advancing multiple near-term Phase 3 clinical studies Demonstrated clinical efficac
Slide 4: Opportunity summary
Opportunity summary Regulatory Complete institutional led FSGS market interactions (US, COVID Ph3 placement (led by opportunity is EU & UK) opportunities Merchant Biotech large (>$1b) and confirmed Ph3 funded and remain on track for first read out later this year design & potential accelerated appro
Slide 5: Three near term value propositions
Three near term value propositions 2021 2022 2023 2024 eo oc ooeomUmCOOCUCOUCUCOOUCOCUCOCUCOUCOUCOOUCOUCOUCUO 1 STUDY CLARITY PHASE 3 COVID-19 i (Respiratory Complications) Primary endpoint Potential emergency use Funded IREMAP-CAP PHASE 3 COVID-19 2 STUDY (COVID-19 pneumonia) Primary endpoint Poten
Slide 6: Board of directors
For personal use only James Williams Nina Webster Hugh Alsop Sonia Poli PhD, MBA PhD, MBA, M.IP.Law BSc (Hons), MBA PhD Non-Executive Chairman CEO & Managing Director Non-Executive Director Non-Executive Director iCeutica, Yuuwa, AdAlta Wyeth (Pfizer), Acrux, Immuron Mayne Pharma, Acrux, Hatchtech,
Slide 7: Management team
For personal use only Nina Webster Hamish George Robert Shepherd Bronwyn Pollock PhD, MBA, M.IP.Law BCom, CA, GIA(Cert) PhD BSc (Hons), MBA CEO & Managing Director CFO & Company Secretary R & D Director Product Development Director Wyeth (Pfizer), Acrux, Immuron Bio101, Pitcher Partners, Medicines D
Slide 8: Top shareholders
For personal use only Top shareholders 8
Slide 9: Key achievements — FY21
Key achievements — FY21 4 al v Phase 3 study in FSGS designed and | vi he preparing to initiate, with other pipeline products also progressing ._ Y Two independent Phase 3 clinical Pal > studies underway in patients with Pe .) COVID-19 respiratory complications nid oe \ q v DMX-200 manufacturing pro
Slide 10: Product candidates in the pipeline
5 product candidates in the pipeline, with 4 clinical opportunities For personal use only 10
Slide 11: Capital raising overview
Capital raising overview
Slide 12: Placement terms
For personal use only • Two tranche placement to raise A$20 million (“Placement”) ▪ A$9.5 million or 47.6 million new Shares under the Company’s existing placement capacity under ASX Listing Rules 7.1 & 7.1A (Tranche 1) ▪ A$10.5 million or 52.4 million new Shares subject to shareholder approval at t
Slide 13: Use of funds
Use of funds n Focal Segmental Glomerulosclerosis (FSGS) to interim data Use of Funds = Clinical m Regulatory uo D IMerx a CMC = Overheads Proposed Expenditure % Clinical 80% Regulatory 6% CMC (manufacturing) 6% Overheads 8% * — Clinical costs quoted by global CRO * Regulatory costs quoted by US reg
Slide 14: For personal use only
For personal use only • • • • • • • • • • • • 14
Slide 15: DMX-200 FSGS kidney disease Phase 2a results
DMX-200 FSGS kidney disease Phase 2a results
Slide 16: Why FSGS: unmet need and market potential
Why FSGS: unmet need and market potential FSGS: rare kidney disease characterized by inflammation and scarring of the kidney’s filtration units, affecting children and adults Renal failure in <5 years from diagnosis — dialysis or transplant “20,000 FSGS patients in US with end-stage kidney disease -
Slide 17: For personal use only
For personal use only • • • • • 17
Slide 18: DMX-200 clinical studies
For personal use only Phase 1 study (DMX-200-101) Phase 2a study (DMX-200-201) Phase 2a study (DMX-200-202) Phase 2 study (DMX-200-203) • Healthy volunteers • Chronic Kidney Disease • Focal Segmental • Diabetic kidney disease ➢ Pharmacokinetic, ➢ Safety and tolerability Glomerulosclerosis ➢ Efficacy
Slide 19: Phase 2a DMX-200-202 (ACTION for FSGS)
For personal use only Phase 2a DMX-200-202 (ACTION for FSGS): Phase 2a, Double-blind, Randomised, Placebo-Controlled, Crossover Study Evaluating the Safety and Efficacy of DMX-200 in Patients with Primary Focal Segmental Glomerulosclerosis who are Receiving Irbesartan • 10 patients enrolled, 7 patie
Slide 20: For personal use only
For personal use only • • • o o o 20
Slide 21: uMCR normalised to baseline v time
For personal use only uMCR normalised to baseline v time N=7, GeoMean 50% 1.5 uMCR normalised 0% 1.0 -50% 0.5 On placebo On active 0.0 0 5 10 15 Time (weeks) • ▪ ▪ 21
Slide 22: DMX-200 FSGS kidney disease Phase 3 design
DMX-200 FSGS kidney disease Phase 3 design
Slide 23: FSGS Phase 3 study primary endpoint
FSGS phase 3 study primary endpoint A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with primary FSGS receiving an ARB Single, seamless Phase 3 study design* Group 1 DMX-200 + ARB DMX-200 + ARB DMX-200 + ARB proteinuria Final results: eGFR
Slide 24: For personal use only
For personal use only • • • • ✓ ✓ ✓ • • • 24
Slide 25: DMX-200 Intellectual property and exclusivity
DMX-200 Intellectual property and exclusivity Intellectual Property “US EU Method of use: any CCR2 antagonist with any ARB for any kidney disease Granted patents* US 9,314,450 US 10,058,555 ti] US 10,525,038 Patent applications with alternative claims filed @w Dimerix Method of use: DMX-200 with irb
Slide 26: DMX-200 COVID-19 respiratory complications
DMX-200 COVID-19 respiratory complications
Slide 27: Funded by European Union through RECOVER project
For personal use only Funded by European Union through H2020 “Rapid European COVID-19 Emergency Research response” (RECOVER) project • • 27
Slide 28: CLARITY 2.0 primary endpoint
CLARITY 2.0 primary endpoint at day 14 + Not hospitalised, no limitations on activities + Not hospitalised, limitation on activities + Hospitalised, not requiring supplemental oxygen Prospective, multi-centre, randomised, double blind, placebo-controlled study in 600 patients in India i. To assess s
Slide 29: COVID-19 and pneumonia market potential
COVID-19 and pneumonia market potential What is Community Acquired Pneumonia (CAP)? * Pneumonia is an acute inflammation of the lungs, caused by an infection by bacteria, viruses, or fungi * COVID-19 pneumonia is cause by SARS-CoV-2 Facts and Figures 9 $17 billion Pre-COVID: Pneumonia responsible fo
Slide 30: Additional longer term propositions
w Dimerix Additional longer term propositions
Slide 31: Additional asset value propositions
Additional asset value propositions Longer term opportunities Diabetic Kidney Disease Chronic Obstructive Pulmonary Disease Diversifying risk and potential sources of revenue COPD Global COPD treatment market (2017) US$14 billion Addressable market US$1.1 billion Key driver is the rise in diabetes g
Slide 32: For personal use only
For personal use only
Slide 33: For personal use only
For personal use only ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ❑ ❑ ❑ ❑ ❑ ❑ ❑ ❑ 33
Slide 34: End of Presentation
DIMERIX End of Presentation 425 Smith St, Fitzroy 3065 Victoria, Australia T. 1300 813 321 E. bd@dimerix.com